SAGE Therapeutics Announces Presentations at Upcoming Scientific Conferences

CAMBRIDGE, Mass., April 9, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced oral and poster presentations at three upcoming scientific conferences. Presentations include data from the Phase 1/2 clinical trial of SAGE-547 as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE), a rare and life-threatening seizure disorder for which there are no approved therapies, and preclinical data for SAGE-689, being developed as an adjunctive intravenous second-line therapy for the treatment of refractory status epilepticus.

Following is a schedule of SAGE's presentations:

5th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures
Title: SAGE 547, for Super-Refractory Status Epilepticus; a Clinical Update
Date: Saturday, April 11, 2015
Time: 6:30 a.m. ET, 11:30 a.m. GMT
Presenter: Steve Kanes, M.D., Ph.D., chief medical officer of SAGE
Oral Session: Satellite Symposium: Neurosteroids
Location: Sherfield Building, Imperial College London (London, UK)
Title: SAGE 689, a Second Generation Neuroactive Steroid for Status Epilepticus
Date: Saturday, April 11, 2015
Time: 6:00 a.m. ET, 11:00 a.m. GMT
Presenter: Al Robichaud, Ph.D., chief scientific officer of SAGE
Oral Session: Satellite Symposium: Neurosteroids
Location: Sherfield Building, Imperial College London (London, UK)
67th American Academy of Neurology (AAN) Annual Meeting
Title: Phase 1/2 Trial of SAGE-547 in Super-Refractory Status Epilepticus
Date: Wednesday, April 22, 2015
Time: 6:15 p.m. ET
Presenter: Steve Kanes, M.D., Ph.D., chief medical officer of SAGE
Oral Session: Emerging Science Platform Session, #004
Poster Session: 7:00 p.m. ET, during the Emerging Science Platform Session
Location: Walter E. Washington Convention Center (Washington, DC)
Antiepileptic Drug and Device Trials XIII Conference
Title: SAGE-547 Phase 1/2 Trial-Final Results: New Directions, New Options in SRSE
Date: Friday, May 15, 2015
Time: 2:50 p.m. ET
Presenter: Steve Kanes, M.D., Ph.D., chief medical officer of SAGE
Oral Session: Session IX: Drug Pipeline, Clinical
Location: Turnberry Isle Miami Hotel (Aventura, FL)

About SAGE-547

SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors. GABAA receptors are widely regarded as validated drug targets for a variety of disorders, with decades of research and multiple approved drugs targeting these receptor systems. SAGE-547 is an intravenous agent entering Phase 3 clinical development as an adjunctive therapy, a therapy combined with current therapeutic approaches, for the treatment of super-refractory status epilepticus (SRSE), as well as in exploratory Phase 2a clinical trials for the treatment of essential tremor and as an adjunctive therapy for the treatment of severe postpartum depression. SAGE plans to begin enrollment of its planned Phase 3 clinical trial in mid-2015. SAGE-547 has been granted both Fast Track and orphan drug designations by the U.S. Food and Drug Administration (FDA) for the treatment of SRSE. The active pharmaceutical ingredient, treatment IND and support for emergency-use patients have been contributed under agreement by the Regents of the University of California and the University of California Davis.

About Status Epilepticus

Status epilepticus (SE) is a life-threatening seizure condition that occurs in approximately 150,000 people each year in the U.S., of which 30,000 SE patients die.i We estimate that there are 35,000 patients with SE in the U.S. that are hospitalized in the intensive care unit (ICU) each year. An SE patient is first treated with benzodiazepines, and if no response, is then treated with other, second-line, anti-seizure drugs. If the seizure persists after the second-line therapy, the patient is diagnosed as having refractory SE (RSE), admitted to the ICU and placed into a medically induced coma.

Currently, there are no therapies that have been specifically approved for RSE; however, physicians typically use anesthetic agents to induce the coma and stop the seizure immediately. After a period of 24 hours, an attempt is made to wean the patient from the anesthetic agents to evaluate whether or not the seizure condition has resolved. Unfortunately, not all patients respond to weaning attempts, in which case the patient must be maintained in the medically induced coma. At this point, the patient is diagnosed as having SRSE. Currently, there are no therapies specifically approved for SRSE.

About SAGE Therapeutics

SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare central nervous system, or CNS, disorders. SAGE's lead program, SAGE-547, is entering Phase 3 clinical development for super-refractory status epilepticus, or SRSE, and is the first of several compounds the Company is developing in its portfolio of potential anti-seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABAA and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders. For more information, please visit

Forward-Looking Statements

Various statements in this release concerning SAGE's future expectations, plans and prospects, including without limitation, SAGE's expectations regarding SAGE-547 as a treatment for SRSE, essential tremor and postpartum depression, statements concerning the potential safety and efficacy of SAGE-547 and durability of response, the timing of discussions with FDA and the outcome of any such discussions, the expected development pathway for SAGE-547 or its other drug candidates and its expectations with respect to the timing and success of its clinical trials, in particular its planned Phase 3 randomized clinical trial for SAGE-547 as a treatment for SRSE, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In particular, it should be noted that the data reported above for SAGE-547 are preliminary in nature. The Phase 1/2 clinical trial has not been completed and the emergency use cases are not part of that clinical trial. There is limited data concerning the safety and efficacy of SAGE-547. These data may not be repeated or observed in ongoing or future studies involving SAGE-547 or SAGE's other product candidates. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, SAGE's ability to successfully demonstrate the efficacy and safety of its drug candidates, the pre-clinical and clinical results for its product candidates, which may not support further development of product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials, obtaining, maintaining and protecting intellectual property, SAGE's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, competition from others developing products for similar uses, SAGE's ability to manage operating expenses, SAGE's ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, SAGE's dependence on third parties for development, manufacture, marketing, sales and distribution of products, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in SAGE's annual report on Form 10-K for the fiscal year ended December 31, 2014, as well as discussions of potential risks, uncertainties, and other important factors in SAGE's subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent SAGE's views only as of today and should not be relied upon as representing its views as of any subsequent date. SAGE explicitly disclaims any obligation to update any forward-looking statements.

i DeLorenzo, Robert J., Pellock, John M., Towne, Alan R., Boggs, Jane G. Epidemiology of Status Epilepticus. J Clin Neuro 1995; 12(4): 316-325.

CONTACT: Investor Contact: Paul Cox, SAGE Therapeutics 617-299-8377 Media Contact: Dan Budwick, Pure Communications 973-271-6085

Source:SAGE Therapeutics